EU relaxes safety monitoring of CAR-T therapies
Drug Discovery World
JUNE 11, 2024
The European Medicines Agency has approved a Type II variation to the Summary of Product Characteristics (SmPC) for Kite’s chimeric antigen receptor (CAR)-T cell therapies, Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel).
Let's personalize your content